WO2021152555A1 - Novel immunotherapy for tumours and cancers, and associated inflammation - Google Patents
Novel immunotherapy for tumours and cancers, and associated inflammation Download PDFInfo
- Publication number
- WO2021152555A1 WO2021152555A1 PCT/IB2021/050766 IB2021050766W WO2021152555A1 WO 2021152555 A1 WO2021152555 A1 WO 2021152555A1 IB 2021050766 W IB2021050766 W IB 2021050766W WO 2021152555 A1 WO2021152555 A1 WO 2021152555A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- tumours
- apolar
- cancers
- picrorhiza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Definitions
- Cancers and tumours are increasing year by year with changes in the life style and aging population. USA alone is having about 650,000 cancer related deaths a year.
- metastatic cancers are with heterogeneity in the cancer cells. Which is making targeted therapies and specific anti-bodies less effective in metastatic cancers.
- PE is for treatment of cancers and tumours and expected to address: -Heterogeneity in cancers and tumours -inflammation associated with cancers and tumours -safe and having less side-effects
- PE is a speciality apolar extract from one or more plants materials selected from Picrorhiza kurrooa Royle, Picrorhiza Scrophulariiflora Pennell and Neopicrorhiza scrophulariiflora. Theses 3 plant species are referred as "PK Plants" in this invention. Where in plants materials are mainly of roots and rhizomes of PK Plants.
- PE is speciality apolar extract which also contains bioactive microRNAs of PK Plants. PE also contains aglycons, steroidal fatty acids and fatty acids of PK Plants.
- PE proved safe and side effects free, even at higher doses. PE could be used in the form of a vaccine or adjuvant to a vaccine or booster dose to increase or create immunity to the cancers or tumours
- PE could also be used for treatment of cancers and tumours below detectable limits and micrometastasis in lymph nodes and other organs.
- PE Since, PE is having potential to modulate immune system, modulate miRNAs, modulate T- Cells, reduce inflammation and has antioxidant effect, PE also can be used for prevention, treatment and management of neurological and neurodegenerative diseases and disorders like Alzheimer's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Autism.
- PE may be further added or co-administered with Vitamins like A, B, C, D, E, K and Anti-oxidants like Lycopene, Astaxanthin, Glutathione and Enzymes which breaks oxidative stress.
- this technology may also be used in other medicinal/herbal plants and herbal extractions which are good for treatment of cancers and tumours, like curcumin longa and other
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present application relates to an Apolar Picrorhiza Extract (PE) of one or more plants selected from the group consisting of Picrorhiza kurroa, Neopicrorhiza scrophulariiflora, and Picrorhiza scrophulariiflora Pennell for prevention, treatment and management of primary and metastatic cancers and tumours, and associated inflammation. PE is also useful for safe and effective treatment and management for paediatric and geriatric primary and metastatic cancers and tumours.
Description
Novel Immunotherapy for tumours and cancers, and associated inflammation
Description of invention:
Cancers and tumours are increasing year by year with changes in the life style and aging population. USA alone is having about 650,000 cancer related deaths a year.
In spite of research and latest medications like immunothepies and targeted nano therapies, one major issue researchers facing is how to manage the inflammation. Being more than 99% genetically similar to normal cells, Cancer is evading body own defence system and causing inflammation which is making difficult to treat cancers and tumours.
One of the major problem with immunotherapy is , it is targeted to particular type of mechanism in the cancer. But metastatic cancers are with heterogeneity in the cancer cells. Which is making targeted therapies and specific anti-bodies less effective in metastatic cancers.
Present invention, it is PE, is for treatment of cancers and tumours and expected to address: -Heterogeneity in cancers and tumours -inflammation associated with cancers and tumours -safe and having less side-effects
-Effective for even childhood and geriatric cancers and tumours -Effective for inoperable brain tumours and solid tumours
Inventor 's research with PE on in-vitro proved it is able to kill cancer cells, mutated cells , but do not kill healthy and normal cells, whereby it is making best possible immunotherapy for cancers and tumours, mainly for treatment of childhood and geriatric cancers and tumours where their body may not be able to withstand for conventional therapies like radiation and chemotherapy.
PE is a speciality apolar extract from one or more plants materials selected from Picrorhiza kurrooa Royle, Picrorhiza Scrophulariiflora Pennell and Neopicrorhiza scrophulariiflora. Theses 3 plant species are referred as "PK Plants" in this invention. Where in plants materials are mainly of roots and rhizomes of PK Plants.
PE is speciality apolar extract which also contains bioactive microRNAs of PK Plants. PE also contains aglycons, steroidal fatty acids and fatty acids of PK Plants.
PE proved safe and side effects free, even at higher doses.
PE could be used in the form of a vaccine or adjuvant to a vaccine or booster dose to increase or create immunity to the cancers or tumours
PE could also be used for treatment of cancers and tumours below detectable limits and micrometastasis in lymph nodes and other organs.
Since, PE is having potential to modulate immune system, modulate miRNAs, modulate T- Cells, reduce inflammation and has antioxidant effect, PE also can be used for prevention, treatment and management of neurological and neurodegenerative diseases and disorders like Alzheimer's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Autism.
For increased efficacy PE may be further added or co-administered with Vitamins like A, B, C, D, E, K and Anti-oxidants like Lycopene, Astaxanthin, Glutathione and Enzymes which breaks oxidative stress.
Since, the process and formulation claimed is able to enhance efficacy, reduce the side- effects and toxicity, reduce the dosage requirement, this technology may also be used in other medicinal/herbal plants and herbal extractions which are good for treatment of cancers and tumours, like curcumin longa and other
Inventor has filed earlier US Patent Appl#20160067292-Bioacive Apolar Extract containing plant genetic material for treatment of mammalian diseases, which is abandoned now.
Claims
1. Apolar Picrorhiza Extract (PE) of one or more plants selected from the group consisting of Picrorhiza kurroa, Neopicrorhiza scrophulariiflora, and Picrorhiza scrophulariiflora Pennell for use in subjects as immunotherapy or immune system modulator in the prevention, treatment or management of tumours and cancers, and associated inflammation
2. The PE as claimed in claim 1 comprises, one or more terpenes, and one or more fatty acids, one or more microRNAs wherein the one or more terpenes, one or more fatty acids, one or more microRNAs are collected during apolar extraction
3. The PE as claimed in claim 1 is further comprises NADPH modulators
4. The PE as claimed in claim 1 is further comprises one or more of the other apolar constituents and its degraded constituents of PK Plants.
5. The PE as claimed in claim 1 is substantially free from sugar moieties and polar components.
6. The PE as claimed in claim 1 is extracted using, but not limited to, apolar solvents like n-hexane, super critical carbon dioxide, super critical carbon dioxide and n-hexane
7. The PE as claimed in claim 1 is formulated in the form of a powder, syrup, drink, tablet, caplet, softgel, capsule, nanogel, nano-particles, injections, parenteral, transdermal patches, absorbent gels, nasal sprays, vaginal gel, and adsorbed on an excipient.
8. Formulation as claimed in claim 7 is further added one or more additional components that provide complementary or supplementary therapeutic efficacy and/or are additional factors for nutrition, food, color, taste, texture, odor, flavor, bulk , stability and other characteristics.
9. Formulation as claimed in claim 7 is in a form suitable for administration through oral, intravenous, intramuscular, Intravesical, sub-cutaneous, peritoneal, rectal, nasal, trans-dermal, dermal, sublingual, vaginal or other routes.
10. Formulation as claimed in claim 7 contains PE as an active or key ingredient in the range of lOmg to 500mg per dose
11. Formulation as claimed in claim 7, formulation is in the form of a food/dietary supplement, a medicine, or an alternative medicine with or without added adjuvants.
12. As claimed in claim 1, wherein the subject is an animal
13. As claimed in claim 1, wherein the subject is a human
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202016779625A | 2020-02-02 | 2020-02-02 | |
| US16/779,625 | 2020-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021152555A1 true WO2021152555A1 (en) | 2021-08-05 |
Family
ID=77079298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2021/050766 Ceased WO2021152555A1 (en) | 2020-02-02 | 2021-02-01 | Novel immunotherapy for tumours and cancers, and associated inflammation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021152555A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011024196A2 (en) * | 2009-08-12 | 2011-03-03 | Munisekhar Medasani | Picrorhiza kurroa extract for prevention, elimination and treatment of dna based viruses in humans and in biotech industry |
-
2021
- 2021-02-01 WO PCT/IB2021/050766 patent/WO2021152555A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011024196A2 (en) * | 2009-08-12 | 2011-03-03 | Munisekhar Medasani | Picrorhiza kurroa extract for prevention, elimination and treatment of dna based viruses in humans and in biotech industry |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE TKDL 2001, "Kukkil Nei-2", XP055846721, Database accession no. GP03/57 * |
| SONI, DEEPIKA ET AL.: ""Picrosides'' from Picrorhiza kurroa as potential anti-carcinogenic agents", BIOMEDICINE & PHARMACOTHERAPY, vol. 109, 2019, pages 1680 - 1687, XP085552081 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fakhri et al. | Effects of polyphenols on oxidative stress, inflammation, and interconnected pathways during spinal cord injury | |
| Ratan et al. | Adaptogenic effects of Panax ginseng on modulation of immune functions | |
| Hosseinzadeh et al. | Pharmacological effects of Glycyrrhiza spp. and its bioactive constituents: update and review | |
| US6395311B2 (en) | Multicomponent biological vehicle | |
| Salama et al. | Experimental and therapeutic trials of amygdalin | |
| CN104688720A (en) | Application of chlorogenic acid in preparation of medicine for treating melanoma and medicine for treating melanoma | |
| JP6218870B2 (en) | Composition for preventing or treating nonalcoholic liver disease or insulin resistance comprising ginsenoside F2 | |
| CN101808654A (en) | Compounds extracted from palm oil mill effluent for cancer treatment, mixtures thereof and methods | |
| WO2021152555A1 (en) | Novel immunotherapy for tumours and cancers, and associated inflammation | |
| Martin | Seaweeds and Their Secondary Metabolites: A Promising Drug Candidate With Novel Mechanisms Against Cancers and Tumor Angiogenesis | |
| Vijayapoopathi et al. | Nutraceutical combination ameliorates imiquimod‐induced psoriasis in mice | |
| Ronald Steriti | Nutritional support for chronic myelogenous and other leukemias: a review of the scientific literature | |
| KR102644398B1 (en) | Immuno Anticancer Composition Containing Rhus Veniciflua Strokes Extract And Cytokine Induced Killer Cells | |
| CN107049999A (en) | Use of lutein for the treatment of cancer | |
| US20170152285A1 (en) | Extracting method of kuguacin, pharmaceutical composition comprising the kuguacin and use thereof | |
| CN104873533A (en) | Application of small-molecular citrus pectin | |
| KR100485936B1 (en) | Anticarcinogenic constituents of ginsenoside Rh2 and Rg3 | |
| Prabakaran et al. | Geraniin: A dietary ellagitannin as a modulator of signalling pathways in cancer progression | |
| Zhang et al. | Research progress on detection and biological activity of astaxanthin. | |
| Hyun et al. | Are berries useless by-products of ginseng? Recent research on the potential health benefits of ginseng berry | |
| Xochitl Sofia et al. | Anti-inflammatory and antitumor properties of Eriobotrya japonica Lindl: Mini-review | |
| CN110538301A (en) | A kind of Sanyeqing compound composition for enhancing antitumor and antioxidant activity and preparation method thereof | |
| Mahmoudi | Nutrition, Immunity, and Cancer | |
| Tenguria et al. | Natural bioactive compounds: An alternate strategy for Glioblastoma multiforme diagnosis and therapy | |
| Martini | Amygdalin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21747954 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21747954 Country of ref document: EP Kind code of ref document: A1 |